Treatment related factors and inhibitor development in children with severe haemophilia A
Authors:
- P. S. MacleanPMP. S. Maclean
- D. M. KeelingDKD. M. Keeling
- D. YoungDYD. Young
- On Behalf Of The Paediatric Working Party Of UkhcdoOUOn Behalf Of The Paediatric Working Party Of Ukhcdo
- 11 November 2010
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 17 (2) , 282-287
Abstract
With the advent of modern factor replacement therapy the most important remaining obstacle to successful treatment in haemophilia A is the development of inhibitory antibodies against Facto VIII (FVIII). This retrospective case control study examined genetic variables and early treatment patterns in severe haemophilia A patients who subsequently developed clinically significant inhibitors to FVIII compared with matched controls who did not. Seventy eight inhibitor patients were identified from 13 UK centers over 25 years (1982-2007). For each case an age matched control was selected. Data on potential genetic and treatment related risk factors were collected for cases and controls. Treatment related data was collected for the first 50 exposure days (EDs) for controls or up to inhibitor development for cases. Risk factors were compared for significance by univariate and multivariate analysis. Of the genetic risk factors, major defects in the FVIII gene and non-caucasian ethnicity were each responsible for approximately 5-fold increases in inhibitor risk. When treatment related variables are considered, high intensity treatment increased inhibitor risk around 2.5 fold whether represented by the presence of peak treatment moments or by high overall treatment frequency. This finding was significant regardless of the timing of the high intensity treatment. Periods of intense treatment associated with surgery for porta-cath insertion were however not found to be associated with increased inhibitor risk. No association was shown between inhibitor development and age at first FVIII exposure, type of FVIII product, or the use of regular prophylaxis. This study confirms treatment-related factors as important risks for inhibitor development in Haemophilia A.Keywords
This publication has 13 references indexed in Scilit:
- Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia AJournal of Thrombosis and Haemostasis, 2007
- Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort studyBlood, 2007
- Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort studyBlood, 2007
- Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia AHaemophilia, 2007
- The epidemiology of factor VIII inhibitorsHaemophilia, 2006
- Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required.British Journal of Haematology, 2006
- Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia ABlood, 2006
- Environmental risk factors for inhibitor development in children with haemophilia A: a case–control studyBritish Journal of Haematology, 2005
- Prophylactic treatment effects on inhibitor risk: experience in one centreHaemophilia, 2005
- The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor developmentHaemophilia, 2001